After stopping a JAK inhibitor in RA, match the next drug to the reason

Design

Multicentre registry cohort (ANSWER)

Population

500 treatment courses after JAK inhibitor discontinuation in rheumatoid arthritis

Primary outcome

Drug retention by reason for prior JAK inhibitor discontinuation

Effect

After inefficacy, abatacept vs JAKi: discontinuation for ineffectiveness HR 2.83 (95% CI 1.20 to 6.70)

When a JAK inhibitor is stopped in rheumatoid arthritis, there is little evidence on what to use next. A Rheumatology analysis of the Japanese ANSWER registry examined 500 treatment courses started after JAK inhibitor discontinuation — TNF inhibitors, IL-6 receptor antibodies, abatacept or another JAK inhibitor — and split them by why the JAK inhibitor had been stopped.

When the first JAK inhibitor had failed, abatacept was more likely than a second JAK inhibitor to be stopped for ineffectiveness (HR 2.83, 95% CI 1.20 to 6.70); TNF inhibitors, IL-6 receptor antibodies and JAK cycling performed similarly. When the first JAK inhibitor had been stopped for adverse events, TNF inhibitors and IL-6 receptor antibodies were associated with fewer subsequent adverse-event discontinuations than another JAK inhibitor. Across all reasons, abatacept had higher discontinuation for ineffectiveness (HR 2.57). Disease activity over 12 months did not differ significantly between groups.

This is observational, and choices were made by clinicians for reasons the analysis cannot fully adjust for. But the principle is simple and fits clinical sense: after inefficacy, another JAK inhibitor is reasonable; after toxicity, switch mechanism.

• Record why a JAK inhibitor was stopped — inefficacy or adverse event — before choosing the next drug.
• After JAK inhibitor inefficacy, another JAK inhibitor, a TNF inhibitor or an IL-6 receptor antibody appear reasonable.
• After a JAK inhibitor adverse event, consider switching mechanism to a TNF inhibitor or IL-6 receptor antibody rather than another JAK inhibitor.
• Abatacept was retained less well after JAK inhibitor failure in this registry.
• Follow current guideline cautions on JAK inhibitors in older patients and those with cardiovascular or cancer risk.

Why it matters

The reason a drug stopped carries information that a simple switch-or-cycle rule ignores.

Don't overread it

These observational associations are subject to confounding by indication and do not prove one sequence is better.

The statistics, in plain English

A hazard ratio of 2.83 means abatacept was stopped for lack of effect at nearly three times the rate of a second JAK inhibitor; the wide interval (1.20 to 6.70) reflects small subgroup numbers.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.